Imidazoles and triazoles represent major classes of antifungal azole derivatives. With respect to UDP-glucuronosyltransferase (UGT) enzymes, the drug metabolism focus has mainly concentrated on their inhibitory effects with little known about azoles as substrates for UGTs. N-Glucuronide metabolites of the imidazole antifungals, tioconazole and croconazole, have been reported, but there are currently no reports of N-glucuronidation of triazole antifungal agents. In this study, evidence for glucuronidation of azole-containing compounds was studied in human liver microsomes (HLM). When a glucuronide metabolite was identified, azoles were incubated in 12 recombinant UGT (rUGT) enzymes, and enzyme kinetics were determined for the UGT with the most intense glucuronide peak. Six imidazole antifungals, three triazoles, and the benzodiazepine alprazolam (triazole) were evaluated in this study. All compounds investigated were identified as substrates of UGT. UGT1A4 was the main enzyme involved in the metabolism of all compounds except for fluconazole, which was mainly metabolized by UGT2B7, probably mediating its O-glucuronide metabolism. UGT1A3 was also found to be involved in the metabolism of all imidazoles but not triazoles. In both HLM and rUGT K m values were lower for imidazoles (14.8-144 M) than for triazoles (158-3037 M), with the exception of itraconazole (8.4 M). All of the imidazoles studied inhibited their own metabolism at high substrate concentrations. In terms of UGT1A4 metabolism, itraconazole showed kinetic features characteristic of imidazole rather than triazole antifungals. This behavior is attributed to the physicochemical properties of itraconazole that are similar to those of imidazoles in terms of clogP.
Glucuronide conjugation is catalyzed by a family of UDP-glucuronosyltransferase (UGT) enzymes and occurs at nucleophilic functional groups containing oxygen (e.g., hydroxyl or carboxylic acid), nitrogen (e.g., amines), sulfur (e.g., thiols), and more rarely carbon (King et al., 2000) . It is therefore not surprising to find that a myriad of compounds, including drugs from all therapeutic classes, dietary chemicals, environmental pollutants, and endogenous substances such as bilirubin and bile acids are cleared by glucuronidation (Miners et al., 2004) . UGTs catalyze nucleophilic attack by the acceptor group of a substrate at the C1 position on the acid ring of UDP-glucuronic acid (UDPGA cofactor), resulting in the formation of UDP and a ␤-Dglucuronide product (King et al., 2000) . UGT proteins are located in the endoplasmic reticulum with the active site situated on the luminal side and in the nuclear envelope membranes (Tephly and Burchell, 1990) . Glucuronidation may occur in most tissues, and, in common with the cytochrome P450 family of enzymes, UGTs abound in the liver. However, some UGT enzymes, such as 1A7, 1A8, 1A10, 2A1, and 2B17 are only expressed in extrahepatic tissues (Tukey and Strassburg, 2000) . The most commonly described pathway is Oglucuronidation, which may have overshadowed N-glucuronidation as discussed during the 1996 ASPET "N-Glucuronidation of Xenobiotics Symposium" (Franklin, 1998) . In an evaluation of the importance of local chemical structure for metabolism by UGT enzymes, most UGT isoforms were found to have a preference for oxygen over nitrogen glucuronidation, with the converse for UGT1A4 (Sorich et al., 2006) . N-Glucuronidation may occur at various functional groups that include alkylamines, arylamines, hydroxylamines, carbamates, ureas, thioureas, and sulfonamides (Hawes, 1998) . UGT1A4 is reported to be the major UGT involved in N-glucuronidation, even though other UGT enzymes may also N-glucuronidate, but to a lesser extent. UGT1A3 and UGT1A4 were thought to be the only two enzymes able to glucuronidate tertiary amines (Miners et al., 2004) ; however, more recently UGT2B10 has been shown to selectively glucuronidate medetomidine, a chiral imidazole, to the N 3 -glucuronide of levomedetomidine (Kaivosaari et al., 2008) . UGT2B10 has not been extensively studied in the literature and may therefore be of greater importance in N-glucuronidation reactions. Multiple examples of glucuronidation of tertiary amines to quaternary ammonium glucuronides have been reported in the literature with classes of compounds such as the tricyclic antidepressants (Lehman et al., 1983; Breyer-Pfaff et al., 1997; Fischer and Breyer-Pfaff, 1997) and azole derivatives (Vashishtha et al., 2001; Kaivosaari et al., 2008) . Of the azole antifungals tioconazole (Macrae et al., 1990) , posaconazole (Ghosal et al., 2004) , and croconazole (Takeuchi et al., 1989) were the only three for which quaternary N-glucuronidation evidence could be found in the literature, and none is reported for triazole antifungals.
However, a number of the azole antifungal agents have been shown to inhibit UGT enzymes. Ketoconazole inhibits UGT 2B7-catalyzed morphine glucuronidation (Takeda et al., 2006) , zidovudine glucuronidation (Sampol et al., 1995) , and recombinant UGT (rUGT) 1A1 and 1A9 catalyzed 7-ethyl-10-hydroxycamptothecin glucuronidation (Yong et al., 2005) . The former researchers reported that although ketoconazole is not known to be a substrate for UGT enzymes, it appears to bind to the substrate binding site of UGT2B7. Competitive inhibition of lorazepam glucuronidation by fluconazole, miconazole, and ketoconazole in vitro with rabbit liver microsomes has also been observed (Sawamura et al., 2000) . In addition, the imidazoles miconazole and ketoconazole were demonstrated to inhibit the glucuronidation of zidovudine by human liver microsomes more potently than the triazoles fluconazole and itraconazole (Sampol et al., 1995) . In general, however, drug-drug interactions as a result of UGT inhibition are modest in magnitude (Williams et al., 2004) . For example, the in vitro inhibition of zidovudine metabolism by fluconazole predicts an area under the curve ratio of 1.4:2.1 compared with the observed value of 1.9 (Uchaipichat et al., 2006b) .
The aim of the current research was to investigate whether imidazole antifungals such as ketoconazole and triazole antifungals such as itraconazole form glucuronides after incubations with human liver microsomes (HLM) and to identify the UGT enzyme(s) involved (see Fig. 1 for structures of the imidazole-and triazole-containing compounds investigated). The benzodiazepine alprazolam (triazole) was also investigated for comparison with recently published data for midazolam (Hyland et al., 2009 Chemistry, Pfizer Ltd. (Sandwich, UK). All were of Ͼ98% purity. Econazole, miconazole, itraconazole, bifonazole, sulconazole, dimethyl sulfoxide, alamethicin, D-saccharic acid 1,4-lactone monohydrate (saccharolactone), and UDPGA were purchased from Sigma-Aldrich (Munich, Germany). Recombinant human UGT enzymes and human liver microsomes were purchased from BD Biosciences (San Jose, CA). All solvents were of high-performance liquid chromatography grade and were purchased from Thermo Fisher Scientific (Schwerte, Germany).
Identification of Glucuronide Metabolites. Human liver microsomes (pool of 60 donors) at 0.5 mg/ml, saccharolactone (5 mM), alamethicin (50 g/mg of protein in incubation), MgCl 2 (10 mM), and Tris-HCl buffer, pH 7.4 (50 mM), were mixed together and preincubated on ice for 15 min. The drug solutions (100ϫ dimethyl sulfoxide stocks) were added to give final concentrations of 1, 10, and 50 M, and the incubation mix was preincubated on ice for a further 5 min. Reaction mixtures were then warmed to 37°C, and the reaction was initiated by addition of UDPGA (5 mM in incubation). Three volumes of ice-cold acetonitrile were added to the reaction mixtures after 1 h of incubation. The samples were centrifuged at 3000g for 1 h at 4°C, and the supernatant was analyzed by LC-mass spectrometry for identification of metabolites.
Glucuronidation of Azole-Containing Drugs in Human Liver Microsomes. Enzyme kinetic experiments were performed in triplicate with human liver microsomes. Incubation times and protein concentrations were optimized by performing time courses for up to 120 min and protein courses up to 2 mg of protein/ml. Table 1 details the various optimum incubation times and protein concentrations for each of the compounds studied. Incubations contained 50 mM Tris-HCl (pH 7.4) buffer, 10 mM MgCl 2 , 5 mM saccharolactone, alamethicin at 50 g/mg of protein, 5 mM UDPGA, and azole substrate (50 nM-1 mM, with a final dimethyl sulfoxide concentration of 1% v/v). Before substrate and UDPGA addition, the reaction mixture was kept on ice for 15 min so that alamethicin, a pore-forming peptide, had time to disrupt the microsomal membrane, because the UGT active site is localized inside the endoplasmic reticulum (Fisher et al., 2000) . After preincubation at 4°C substrate was added, and the reaction mixture was warmed to 37°C. Incubations were initiated by addition of UDPGA and terminated with 3 volumes of ice-cold acetonitrile containing 13.3% of formic acid. Samples were centrifuged at 3000g for 45 min, and the supernatant was analyzed by LC-MS/MS.
UGT Phenotyping. To identify the UGT enzyme(s) responsible for glucuronidation of the azole-containing drugs being tested time courses under the assay conditions described above were performed with the following recombinant UGT enzymes: UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15, and UGT2B17 at 0.25 mg of protein/ml in the incubation in quadruplicate. Enzyme kinetic experiments were performed in triplicate, except where stated, with the recombinant UGT enzyme identified in the UGT phenotyping experiment as being the main enzyme involved. Experimental conditions were the same as described above.
Enzyme Kinetics Analysis. Reaction rates were calculated as peak area of glucuronide per milligram of protein per minute because metabolite standards were not available. The apparent kinetic parameters K m , relative V max , and K i (where substrate inhibition was observed) were determined using GraFit 5.0 software (Erithacus Software Ltd., Horley, Surrey, UK). When data fitted the Michaelis-Menten equation, the following equation was applied:
When substrate inhibition was observed the following equation (Houston and Kenworthy, 2000) was applied:
where K i is the dissociation constant for the inhibitory substrate-enzymesubstrate complex. Analytical Conditions. For metabolite identification accurate mass determinations of parent compound and glucuronide conjugates were performed on a Waters Q-Tof Premier mass spectrometer (Waters Ltd., Elstree, Herts, UK) operating in "V" mode using leucine-enkephalin (m/z 556.2771) as the lock spray internal mass calibrant. The instrument was operated under positive ion mode for full scanning acquisitions between m/z 100 and m/z 800 at 0.3 s/scan. The LC system consisted of an 1100 binary pump (Agilent Technologies Inc., Palo Alto, CA) and a CTC Analytics HTS PAL autosampler (Presearch Ltd., Basingstoke, Hants, UK). Parent compound and glucuronide metabolites were resolved on a SunFire 3.5-m C18 (100 ϫ 2.1-mm i.d.) column (Waters Ltd.) with a linear gradient of acetonitrile (5-98% over 8 min) in water, both containing 0.1% (v/v) formic acid, at a flow rate of 0.2 ml/min. Nitrogen was used as both the nebulizing and desolvation gas. The source and desolvation temperatures were 120 and 300°C, respectively, the capillary voltage was 3.2 kV, and the sample cone voltage was 25 V. MS/MS analysis was performed at a collision energy of 20 eV using argon as the collision gas. Data were processed with MassLynx 4.0 sp4 (Waters Ltd., Manchester, UK).
For LC-MS/MS quantitation a triple quadrupole mass spectrometer (API4000; AB Sciex, Warrington, Chesire, UK) was interfaced with X-LC binary pumps (Jasco UK, Ltd., Great Dunmow, Essex, UK) and a CTC Analytics HTS PAL autosampler. The instrument was operated in the positive ion mode using a TurboIonSpray interface. Compounds were injected onto a Synergi 2.5-m fusion 30 ϫ 2.0-mm column (Phenomenex, Torrance, CA) and eluted using a gradient method starting at 97% aqueous, going down to 10% over 0.6 min, going back to 97% at 0.61 min, and holding at 97% aqueous for a further 0.5 min, all at a flow rate of 1 ml/min. Aqueous solvent contained 95% high-performance liquid chromatography grade water, 5% acetonitrile, and 0.1% formic acid; organic solvent consisted of 100% acetonitrile and 0.1% formic acid. The different transitions selected for each of the compounds are detailed in Table 1 .
Results
Identification of Glucuronide Metabolites. All of the compounds tested underwent glucuronidation to various extents. Based on peak intensity, econazole, miconazole, tioconazole, bifonazole, sulconazole, and ketoconazole showed more extensive glucuronidation with glucuronide formation being at least 1 order of magnitude higher than that for alprazolam, fluconazole, voriconazole, and itraconazole. For all imidazole-containing compounds, based on fragmentation patterns, (Macrae et al., 1990) , posaconazole (Ghosal et al., 2004) , and croconazole (Takeuchi et al., 1989) , it is assumed that glucuronides forming on the imidazole or triazole rings are quaternary N-glucuronides. Enzyme Kinetics of Azole Glucuronidation in Human Liver Microsomes. Time linearity varied from one azole compound to the other, and incubation times are detailed in Table 1 . The glucuronide formation rate was proportional to the microsomal protein concentration up to 1 mg of protein/ml for all compounds studied. Itraconazole and all imidazole antifungal compounds fitted the substrate inhibition model described under Materials and Methods because the glucuronide formation rate started decreasing at high substrate concentrations. The remaining substrates showed Michaelis-Menten behavior. Examples of typical Michaelis-Menten kinetics and substrate-inhibition kinetics in HLM are shown in Fig. 2 .
Relative V max , K m , and K i values obtained from incubations of azole compounds in HLM are summarized in Table 2 . Relative V max values are reported as peak area per minute per milligram of protein as authentic standards of the glucuronides of interest were not available. Relative V max values ranged from 29 to 447 peak area/min/mg of protein for triazole compounds and from 1158 to 25,600 peak area/min/mg of protein for imidazole compounds. K m values ranged from 14.8 to 144 M with imidazoles and from 8.4 to 3037 M with triazoles.
rUGT Phenotyping. All compounds were incubated with 12 individual rUGT enzymes 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17 to identify the enzyme(s) responsible for the glucuronidation of azoles. Examples of typical bar charts of the screening results are shown in Fig. 3 . Table 3 summarizes the involvement of individual UGT enzymes in the metabolism of azole compounds. rUGT1A4 was the main enzyme responsible for azole glucuronidation except for fluconazole, for which rUGT2B7 was flagged as the main enzyme involved.
Enzyme Kinetics in rUGT1A4 (rUGT2B7 for Fluconazole). With the exception of fluconazole, rUGT1A4 was found to be the major catalyzing enzyme for drug glucuronidation in vitro. Hence enzyme kinetics were determined using rUGT1A4 for all compounds but fluconazole, for which UGT2B7 was used. All imidazole antifungal compounds fitted the substrate inhibition model as for HLM. Alprazolam, fluconazole, and voriconazole fitted the Michaelis-Menten model. Examples of the Michaelis-Menten kinetics and substrate inhibition kinetics in rUGT are shown in Fig. 4 .
Relative V max , K m , and K i values obtained from incubations in rUGT enzymes are summarized in Table 4 . Relative V max values ranged from 170 to 436 peak area/min/mg of protein for triazole compounds. Relative V max values ranged from 541 to 31,445 peak area/min/mg of protein for imidazole compounds. K m values ranged from 7 to 124 M with imidazoles and from 261 to 1667 M with triazoles. Poor assay sensitivity for itraconazole precluded accurate determination of a K m value; however, the K m appeared to be low (Ͻ10 M), in keeping with the value observed in human liver microsomes.
Consideration of Physicochemical Properties. Lipophilicity values (clogP) and dissociation constants relative to the azole moiety (pK a ) were obtained from the ACDLABS 11.0 database and are tabulated in Table 5 . All imidazoles had high pK a values compared with triazoles, whereas in terms of clogP the triazoles were generally less lipophilic than the imidazoles, with the exception of itraconazole and posaconazole with clogP values in the same range as the imidazoles.
Discussion
Although studies have been performed on the effects of antifungals acting as inhibitors of glucuronidation (Sampol et al., 1995; Takeda et al., 2006) , this study highlights their ability to also act as substrates of UGT. ). This method was used successfully in the present study to demonstrate that all of the compounds examined were susceptible to glucuronidation. The size of the glucuronide peaks for the imidazoles were at least an order of magnitude greater than those for the triazoles, suggesting that imidazoles may be more susceptible to glucuronidation than triazole compounds.
Transitions from mass spectrometric data suggest that with the exception of fluconazole all of the glucuronides detected were formed at nitrogen atom(s) in the imidazole or triazole ring, hence confirming that N ϩ -glucuronidation is a relevant pathway in human metabolism of drugs containing a tertiary amine group. Whereas C-glucuronidation cannot be ignored, existing data for posaconazole, croconazole, and tioconazole support N-glucuronidation for this series of compounds (Takeuchi et al., 1989; Macrae et al., 1990; Ghosal et al., 2004) . It has been reported that the various types of N-glucuronide metabolites differ markedly in their susceptibility to chemical hydrolysis, and, in general, the N-glucuronide metabolites of primary and secondary amines are very unstable in solution below pH 7. N ϩ -glucuronides, on the other hand, tend to be stable in acidic solutions (Hawes, 1998 ). In the current study, incubations were terminated by addition of acidified acetonitrile, and glucuronides could be detected, which provides further evidence that quaternary ammonium-linked glucuronides of azole compounds were being formed.
In the current study, UGT enzyme kinetics of various imidazole and triazole antifungal agents and one benzodiazepine (fused triazolebenzodiazepine ring) were initially investigated in human liver microsomes. After reaction phenotyping with 12 different recombinant UGT enzymes, UGT1A4 was identified as the main enzyme involved in the glucuronidation of all compounds tested with the exception of fluconazole, for which UGT2B7 was primarily responsible for its glucuronidation. Enzyme kinetics with recombinant UGT1A4 and UGT2B7 in the case of fluconazole were subsequently investigated.
The triazoles, alprazolam, voriconazole, and fluconazole, obeyed Michaelis-Menten kinetics and showed low affinity for the enzyme responsible for their glucuronidation, as shown by the high K m values in summary Table 5 . It is thought that because of the presence of the hydroxyl group (-OH) in the chemical structure of fluconazole the O-glucuronide is preferentially formed. Further evidence that the Oglucuronide of fluconazole was preferentially formed over the N-glucuronide was that UGT2B7 rather than UGT1A4 was identified as the main enzyme responsible for its metabolism. Current literature information suggests that only UGT1A3, UGT1A4, and UGT2B10 can form quaternary ammonium-linked glucuronides (Miners et al., 2004; Kaivosaari et al., 2008) ; hence, a fluconazole glucuronide-formed UGT2B7 is unlikely to be the N-glucuronide. UGT1A4 was also found to be involved in fluconazole metabolism, but a low LC-MS/MS signal precluded us from running enzyme kinetics with rUGT1A4. A second triazole, alprazolam, was found to be solely metabolized by UGT1A4.
Itraconazole and all the imidazoles investigated did not obey Michaelis-Menten kinetics because above a critical substrate concentration a decrease in metabolite formation rate was observed; hence, a substrate inhibition model was fitted to the data. It is often the case that a Michaelis-Menten model fits UGT enzyme kinetics satisfactorily; however, in recent years non-Michaelis-Menten kinetics for the glucuronidation of a number of drugs have been described, including biphasic and autoactivation kinetics (Fisher et al., 2000; Lewis et al., 2007; Iwuchukwu and Nagar, 2008; Uchaipichat et al., 2008; Hyland et al., 2009 ). Substrate inhibition, as observed here, is characterized by a second molecule of substrate binding to the enzyme-substrate complex, thereby forming a ternary complex substrate-enzyme-substrate. K i represents the dissociation constant of the ternary complex; i.e., it is an (inverse) estimation of the affinity of the substrate to a second inhibitory binding site on the enzyme. High K i values will indicate a low affinity for the enzyme-substrate complex (Pufall and Graves, 2002) . Substrate inhibition has been reported in the literature for a 
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dmd.aspetjournals.org number of UGT enzymes, including UGT1A4 (Uchaipichat et al., 2006a; Iwuchukwu and Nagar, 2008) . Itraconazole, the benzodiazepine midazolam (Klieber et al., 2008; Hyland et al., 2009) , and the imidazole antifungals currently investigated all showed higher affinity for UGT enzymes than alprazolam, voriconazole, or fluconazole in HLM (see summary Table 5 ). They were all metabolized by UGT1A4 primarily, even though the involvement of other UGT enzymes (UGT1A3 and UGT2B7 mainly) was identified with all imidazoles, except ketoconazole. Posaconazole, an antifungal agent structurally related to itraconazole, is reported to have K m values similar to those of itraconazole: K m values of 27.9 M in human liver microsomes and 15.9 M in UGT1A4 (Ghosal et al., 2004 ). In the current study, the K m values determined in rUGT were within 2-to 3-fold of values observed in HLM (with the exception of tioconazole). Similar trends were observed in terms of alprazolam, voriconazole, and fluconazole showing lower affinity for UGT enzymes compared with the remaining compounds in the series.
Lipophilicity values, dissociation constants relative to the azole moiety (pK a ), and enzyme kinetic values are tabulated in summary Table 5 for each of the azole agents studied and for midazolam (Hyland et al., 2009 ) and posaconazole (Ghosal et al., 2004) . In both HLM and rUGT, a similar trend was observed in terms of K m values, with all the imidazoles having higher affinity for UGT metabolism, along with itraconazole and posaconazole. In terms of structureactivity relationships, it has previously been reported that the steric and electronic character immediately local to the nucleophilic atom is an important predictor for glucuronidation (Sorich et al., 2006) , and for many UGTs the attachment of an aromatic ring to the nucleophile and the type of nucleophile increases the likelihood for glucuronidation. From an evaluation of physicochemical properties, it was observed that all the imidazole nucleophiles were more basic than the triazoles (pK a 6.03-6.88 for imidazoles compared with 2.44 -2.94 for triazoles). However, for this group of compounds, pK a alone could not account for the differences observed in affinity for UGT1A4, with two of the triazoles (itraconazole and posaconazole) having K m values of an order of magnitude similar to that of the imidazole compounds. For UGT1A4, a two-dimensional-quantitative structure-activity relationship modeling technique has highlighted the importance of hydrophobicity in substrate-enzyme binding (Smith et al., 2003) . For these azole compounds, the impact of lipophilicity is also clear, with the compounds exhibiting higher substrate affinity (all imidazoles, posaconazole, and itraconazole) being more lipophilic than the remaining low-affinity triazoles (clogP values between 3.8 and 4.97 for imidazoles, 4.99 for itraconazole, and 4.67 for posaconazole versus 0.45-1.92 for triazoles). In addition, a study by Vashishtha et al. (2002) has shown that quaternary ammonium-linked glucuronidation of 1-substituted imidazoles by liver microsomes was also influenced by lipophilicity. They reported that the greater the lipophilicity of the imidazole derivative, the higher the enzyme affinity. A similar relationship was observed here.
It is important to also consider the role microsomal binding will play on K m for this group of compounds. In particular, for the more lipophilic molecules with clogP Ͼ4 the free K m will be significantly lower than total K m . Two algorithms for the prediction of fraction unbound in the incubation have been proposed (Austin et al., 2002; Hallifax and Houston, 2006) , and both are based upon the lipophilicity of compounds. All of the UGT1A4 substrates here have a clogP Ͼ1 and will probably have a lower free K m . If correction for microsomal binding were incorporated, it is expected that the relationship discussed above would become more distinct, with the most lipophilic compounds (clogP Ͼ3.8) having an even lower free K m than less lipophilic triazoles (clogP 1.21 and 1.92). The situation is slightly different for the UGT2B7 substrate fluconazole, because addition of albumin to incubations indicates that for UGT2B7 a lower true K m is observed as a result of sequestering inhibitory fatty acids released from the incubation (Rowland et al., 2007) .
In summary, it has been demonstrated that all of the imidazole and triazole compounds investigated are substrates for UGT enzymes, 
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dmd.aspetjournals.org particularly UGT1A4. The imidazole-containing compounds were shown to have a greater affinity for UGT1A4 than triazole-containing compounds with the exception of itraconazole and posaconazole. The higher affinity of itraconazole and posaconazole for UGT metabolism compared with that of other triazoles could be explained by physicochemical properties. Although data indicating that some of these compounds can inhibit UGT2B7 already exist in the literature, with imidazoles being more potent inhibitors than triazoles (Sampol et al., 1995; Takeda et al., 2006) , it is highly likely that they will also be inhibitors of UGT1A4. Based on the K m values for UGT1A4, it is also likely that imidazoles will exhibit greater inhibitory potency than triazole agents, with itraconazole and posaconazole as the exceptions. 
